New pill combo aims to tame bone marrow cancer
NCT ID NCT07340138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects and how the drug moves through the body. If results are promising, larger studies may follow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pelabresib (a drug taken as a pill) added to ruxolitinib (another pill)
What this could lead to
If it works, this could point toward a better combination treatment for myelofibrosis, potentially improving symptoms or slowing the disease.
What could go wrong
This is a very early, small study (only 6 people) focused on safety. It may not show clear benefit, and side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGKamogawa, Chiba, 296-8602, Japan
-
Novartis Investigative Site
RECRUITINGSapporo, Hokkaido, 0030006, Japan
-
Novartis Investigative Site
RECRUITINGKamakura, Kanagawa, 247-8533, Japan
-
Novartis Investigative Site
RECRUITINGKurashiki, Okayama-ken, 7108602, Japan
-
Novartis Investigative Site
RECRUITINGBunkyo Ku, Tokyo, 1138431, Japan
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGChūō, Yamanashi, 409-3898, Japan
-
Novartis Investigative Site
RECRUITINGKumamoto, 862-8655, Japan